Blog
Technical depth, clinical context, and the standards work happening at the intersection of precision medicine and health interoperability.
Latest Post
A jargon-free explanation of FHIR (the common language of health data) and HL7 CodeX (the community putting it to work in oncology, cardiovascular care, and genomics) — and why they decide whether your records can follow you.
Read Post →More Featured
A paper our team contributed to has been accepted by AMIA — applying GA4GH Cat-VRS and HL7 FHIR Genomics to automate complex-variant annotation. Led by intern Yazna Penmetsa.
Read Post →Rural cancer death rates run 14% higher than urban; 5-year survival is 8% lower — and the gap is widening. Why the real divide is distance from specialty resources.
Read Post →One in three rural hospitals is at risk of closure. The case for the Hub and Spoke model — and what closure really costs a community.
Read Post →More Posts
Six clinical solutions — cardiovascular, oncology, pain management, pharmacogenomics, chronic disease, and maternal health — all operational on a single FHIR R6-native platform.
Intersect joins HL7 CodeX as an invited Developer/Implementer member — active in the Molecular Tumor Board and Pathogen Genomics workgroups.
Coming Soon
The clinical case for matching variants to individual agents — erlotinib vs. gefitinib vs. osimertinib — rather than drug classes.
Why we chose FHIR R6 before it was finalized, and what that decision means for interoperability with Epic, Cerner, and any SMART-enabled system.
The same CYP2D6 result matters to the oncologist, the cardiologist, the psychiatrist, and the primary care physician. Here’s why most platforms miss this.